Shilpa Medicare's Recombinant Human Albumin 20% (rHA) is derived from yeast and offers a highly purified, structurally and ...

Recombinant influenza vs standard dose inactivated influenza vaccines elicited more robust humoral immune responses at 1- and 6-months postvaccination.

Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...

Their portfolio covers human plasma and serum samples from normal donors as well as Alzheimer’s patients, recombinant ...

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is excited to announce ...

GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial ...

Indian registry confirms mechanical thrombectomy for stroke is cost-effective, with excellent outcomes, but underutilized due ...

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical ...

GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Monetary Damages Due from Sanofi/Novartis Litigation Settlement On 11, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a settlement in the patent ...